Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock. Both option grants have an exercise price of $3.90 per share and expire on April 24, 2036.
One option for 95,333 shares was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments thereafter. A second option for 70,000 shares was granted under the same plan in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026.
AGENUS INC director Thomas L. Harrison received a compensation-related stock option grant rather than making an open-market trade. On the grant date, he was awarded options to acquire 122,500 shares of Common Stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The filing shows he holds options for 122,500 shares after this grant, and a footnote explains the award was made under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date.
AGENUS INC director Timothy Wright received a stock option grant as equity compensation. The award covers 105,000 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The option was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests on the one-year anniversary of the grant date. Following this grant, Wright holds stock options for 105,000 underlying shares directly.
AGENUS INC principal accounting officer Austin Charette received two stock option awards as compensation. On April 24, 2026, Charette was granted options to purchase 17,619 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. These options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments.
Charette also received an additional option grant covering 5,000 shares of common stock at the same $3.90 exercise price, also expiring on April 24, 2036. This second grant was awarded in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026. Both transactions are compensation-related grants, not open-market purchases or sales.
Agenus Inc. director and officer Armen Garo H received three stock option awards on April 24, 2026. Each option allows him to purchase Agenus common stock at an exercise price of $3.90 per share and expires on April 24, 2036. One award is scheduled to vest over three years beginning April 24, 2027, and another was granted in lieu of his 2025 annual cash bonus and will vest in full on May 24, 2026.
Agenus Inc. director Brian Corvese received a grant of 210,000 stock options for Agenus Inc. common stock. The options were awarded on April 24, 2026 under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan at an exercise price of $3.90 per share.
The award vests on the one-year anniversary of the grant date and expires on April 24, 2036. After this grant, Corvese holds 210,000 stock options directly. This is a compensation-related award rather than an open-market share purchase or sale.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
Agenus Inc. seeks stockholder approval of equity proposals while summarizing 2025–early 2026 clinical, commercial and financial progress. Management highlights durable BOT+BAL survival data presented at ESMO, reimbursed compassionate-access revenues recognized in France, enrollment start of the registrational Phase 3 BATTMAN trial, and a transaction that improved liquidity.
The proxy asks for (i) a 5,000,000-share increase to the 2019 Equity Incentive Plan and (ii) a one-time option exchange with executive/director replacement options struck at 150% of the exchange-date market price. The CEO urges support to preserve the team and continue BATTMAN, expanded access, and regulatory engagement.
HARRISON THOMAS L reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director Thomas L. Harrison received 9,228 shares of common stock as a grant under the company’s Board Compensation Election Policy. These shares represent director fees taken in stock rather than cash at an average price of $3.319 per share. After this award, Harrison directly holds 38,998 common shares.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,629 shares of Common Stock as fully vested compensation in lieu of cash salary for the pay period ending April 3, 2026. The shares were valued using the $3.33 closing price on April 2, 2026. After this grant, he directly holds 339,147 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares through a GRAT and a partnership in which he has investment authority and a partial pecuniary interest.